How should gout be managed in a patient with bipolar disorder, especially concerning lithium‑induced hyperuricemia and the choice of acute and chronic gout therapies?

Managing Gout in Patients with Bipolar Disorder

Start with allopurinol as first-line urate-lowering therapy at a low initial dose (≤100 mg/day, lower if CKD present) with gradual titration, while continuing lithium therapy for bipolar disorder, as lithium-induced hyperuricemia does not contraindicate standard gout management. 1

Acute Gout Management

For acute gout flares in bipolar patients on lithium, choose between:

• Corticosteroids (preferred in this population)
• Low-dose colchicine (1.2 mg followed by 0.6 mg one hour later)
• NSAIDs (use cautiously due to potential lithium interaction)

The 2020 ACR guideline strongly recommends all three options as equally effective for acute gout 1. However, corticosteroids may be the safest choice in bipolar patients on lithium, as NSAIDs can increase lithium levels by reducing renal clearance, potentially causing lithium toxicity 2. Low-dose colchicine is as effective as high-dose regimens with better tolerability 1.

Chronic Urate-Lowering Therapy

First-Line Treatment: Allopurinol

Allopurinol remains the strongly recommended first-line agent for all gout patients, including those with bipolar disorder on lithium 1. The guideline explicitly states allopurinol is preferred over all other urate-lowering therapies due to efficacy, tolerability, safety, and cost.

Critical dosing strategy:

• Start at ≤100 mg/day (even lower if CKD stage ≥3 present)
• Titrate gradually to achieve target serum uric acid <6 mg/dL
• Maximum FDA-approved dose is 800 mg/day
• Lower starting doses reduce risk of allopurinol hypersensitivity syndrome 1

Alternative Options

If allopurinol fails or is not tolerated:

• Febuxostat: Start at ≤40 mg/day with gradual titration 1
• Probenecid: Avoid if CKD stage ≥3; xanthine oxidase inhibitors strongly preferred in renal impairment 1
• Pegloticase: Strongly recommended against as first-line therapy 1

The Lithium-Hyperuricemia Connection

Recent research demonstrates that elevated uric acid levels correlate with bipolar disorder severity, particularly in manic episodes 3, 4. Patients with bipolar mania show significantly higher serum uric acid levels (5.2±0.9 mg/dL) compared to those with bipolar depression (4.8±1.0 mg/dL) 3.

Important finding: Treatment with mood stabilizers including lithium, valproate, or carbamazepine all effectively reduce serum uric acid levels equally 3. This suggests the hyperuricemia may be more related to the bipolar disorder itself rather than solely medication-induced.

Do not discontinue lithium to manage hyperuricemia or gout. Lithium remains the gold standard for bipolar disorder, being the only drug effective in prophylaxis of manic, depressive, and suicidal symptoms 5. The FDA label confirms lithium's critical role in reducing frequency and intensity of manic episodes 2.

Prophylaxis During ULT Initiation

Strongly recommended: Initiate concomitant anti-inflammatory prophylaxis when starting urate-lowering therapy 1. Options include:

• Colchicine (preferred if no contraindications)
• NSAIDs (use cautiously—monitor lithium levels closely)
• Prednisone/prednisolone (safest option in this population)

Continue prophylaxis for several months while titrating ULT to target.

Critical Monitoring Considerations

Renal function surveillance is essential in patients on both lithium and gout therapy:

• Lithium can cause nephrogenic diabetes insipidus and progressive renal changes 2
• Chronic kidney disease affects both lithium dosing and choice of urate-lowering therapy
• Monitor serum creatinine, lithium levels, and uric acid levels regularly
• Assess for polyuria/polydipsia suggesting lithium-induced renal effects 2

Common Pitfalls to Avoid

1. Never use NSAIDs without monitoring lithium levels—they reduce renal lithium clearance and can precipitate toxicity
2. Don't avoid treating gout due to lithium therapy—standard gout management applies
3. Don't stop lithium to manage hyperuricemia—treat both conditions simultaneously
4. Don't start allopurinol at high doses—this increases flare risk and hypersensitivity syndrome
5. Don't use probenecid if CKD present—xanthine oxidase inhibitors strongly preferred 1

Treatment Algorithm

1. Acute flare: Corticosteroids first-line (safest with lithium) or low-dose colchicine
2. Initiate ULT: Start allopurinol ≤100 mg/day with anti-inflammatory prophylaxis (prednisone preferred)
3. Titrate to target: Increase allopurinol dose every 2-4 weeks to achieve serum uric acid <6 mg/dL
4. Continue lithium: Maintain bipolar disorder treatment unchanged
5. Monitor closely: Check lithium levels, renal function, and uric acid regularly

The evidence strongly supports that gout and bipolar disorder can be effectively managed concurrently without compromising treatment of either condition 1, 3, 5.